Literature DB >> 30775814

Overexpression of UBR5 promotes tumor growth in gallbladder cancer via PTEN/PI3K/Akt signal pathway.

Zhen Zhang1,2, Xin Zheng3,2, Jiaxin Li3,2, Jutao Duan4, Lihua Cui2, Lei Yang2, Lanqiu Zhang2, Qi Zhang2, Ximo Wang2.   

Abstract

As a key regulator of the ubiquitin-proteasome system, ubiquitin protein ligase E3 component N-recognin 5 (UBR5) plays an important role in various cancers. In this study, our results showed for the first time that UBR5 was overexpressed in gallbladder cancer (GBC) tumor tissues. UBR5 overexpression was significantly associated with tumor size, histological and tumor differentiation. UBR5 overexpression was also associated with poor prognosis in patients with GBC. The knockdown of UBR5 remarkably inhibited the cell proliferation and colony formation of GBC-Shandong (SD) cells in vitro and in vivo. UBR5 potentially increases the level of protein kinase B phosphorylation via the degradation of phosphatase and tensin homolog, which contributes to tumor growth in GBC. UBR5 may be an important biomarker for predicting the prognosis of patients with GBC.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  gallbladder cancer; phosphatase and tensin homolog; proliferation; tumor growth; ubiquitin protein ligase E3 component N-recognin 5

Year:  2019        PMID: 30775814     DOI: 10.1002/jcb.28431

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells.

Authors:  Samantha A Swenson; Tyler J Gilbreath; Heather Vahle; R Willow Hynes-Smith; Jared H Graham; Henry C-H Law; Catalina Amador; Nicholas T Woods; Michael R Green; Shannon M Buckley
Journal:  Blood       Date:  2020-07-16       Impact factor: 22.113

Review 2.  The role of PI3K/AKT signaling pathway in gallbladder carcinoma.

Authors:  Zeyu Wu; Xiao Yu; Shuijun Zhang; Yuting He; Wenzhi Guo
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

3.  UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer.

Authors:  Bingbing Wu; Mei Song; Qun Dong; Gang Xiang; Jing Li; Xiaojing Ma; Fang Wei
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

4.  E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.

Authors:  Jin Li; Wei Zhang; Jian Gao; Min Du; Huimin Li; Mengge Li; Hui Cong; Yuan Fang; Yiyi Liang; Dan Zhao; Gang Xiang; Xiaojing Ma; Ming Yao; Hong Tu; Yu Gan
Journal:  Front Oncol       Date:  2021-03-12       Impact factor: 6.244

5.  UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.

Authors:  Kumar Saurabh; Parag P Shah; Mark A Doll; Leah J Siskind; Levi J Beverly
Journal:  BMC Cancer       Date:  2020-08-31       Impact factor: 4.430

6.  UBR5 oncogene as an indicator of poor prognosis in gastric cancer.

Authors:  Fanghui Ding; Xiaoliang Zhu; Xiaojing Song; Pei Yuan; Longfei Ren; Changpeng Chai; Wence Zhou; Xun Li
Journal:  Exp Ther Med       Date:  2020-08-25       Impact factor: 2.447

Review 7.  Overview of current targeted therapy in gallbladder cancer.

Authors:  Xiaoling Song; Yunping Hu; Yongsheng Li; Rong Shao; Fatao Liu; Yingbin Liu
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

8.  Molecular Characterization and Clinical Relevance of RNA Binding Proteins in Colorectal Cancer.

Authors:  Zhen Zhang; Ling Wang; Quan Wang; Mengmeng Zhang; Bo Wang; Kewei Jiang; Yingjiang Ye; Shan Wang; Zhanlong Shen
Journal:  Front Genet       Date:  2020-10-16       Impact factor: 4.599

9.  MicroRNA-361-5p slows down gliomas development through regulating UBR5 to elevate ATMIN protein expression.

Authors:  Mingming Zhang; Mengqiang Yu; Jiaoying Jia; Zhu Ouyang; Ming Wang; Wenjia Ma; Min Liu
Journal:  Cell Death Dis       Date:  2021-07-28       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.